Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HER2-targeted therapies in cancer: a systematic review
Kunrui Zhu, Xinyi Yang, Hebei Tai, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 24

Showing 24 citing articles:

Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates
Liliana Ascione, Lorenzo Guidi, Ajay Prakash, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 10
Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer
J.H. Lee, Jinhoo Song, Wonbeak Yoo, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
Construction and characterization of chimeric FcγR T cells for universal T cell therapy
Juanjuan Zhao, Manling Chen, Xudong Li, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Efficacy of a novel interstitial lung disease monitoring program in breast cancer patients undergoing treatment with trastuzumab-deruxtecan
Julie Williamson, Kristen Kelley, Mary Beth Scholand, et al.
Breast Cancer Research and Treatment (2025)
Open Access
Cannabinoids as Promising Inhibitors of HER2-Tyrosine Kinase: A Novel Strategy for Targeting HER2-Positive Ovarian Cancer
Thomanai Lamtha, Nathjanan Jongkon, Tossaporn Lertvanithphol, et al.
ACS Omega (2025) Vol. 10, Iss. 6, pp. 6191-6200
Open Access
Exome‐wide molecular insights from blood and urine liquid biopsies in genitourinary cancers
Eric Jia, Tiantian Zheng, Yong Huang, et al.
UroPrecision (2025)
Open Access
From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates
Heidi Ko, Kyle C. Strickland, Dana Jaggessarsingh, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Leveraging HER2-targeted Biparatopic Antibodies in Solid Tumors
Xinlin Liu, Xinyi Fan, Xiang Gao, et al.
Pharmacological Research (2025), pp. 107687-107687
Open Access
Applicability of Quantum Dots in Breast Cancer Diagnostic and Therapeutic Modalities—A State-of-the-Art Review
Dominika Kunachowicz, Karolina Kłosowska, N. Sobczak, et al.
Nanomaterials (2024) Vol. 14, Iss. 17, pp. 1424-1424
Open Access | Times Cited: 4
Trastuzumab-Deruxtecan: Redefining HER2 as a Tumor Agnostic Biomarker
Joseph Zouein, Elias Karam, John H. Strickler, et al.
Targeted Oncology (2024) Vol. 19, Iss. 5, pp. 705-710
Closed Access | Times Cited: 3
AVERON Notebook to discover actionable cancer vulnerabilities enabled by neomorph protein-protein interactions.
Hongyue Chen, Brian Revennaugh, Haian Fu, et al.
iScience (2024) Vol. 27, Iss. 6, pp. 110035-110035
Open Access | Times Cited: 2
Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer
Shannon L. Carey-Smith, Rishi S. Kotecha, Laurence C. Cheung, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6815-6815
Open Access | Times Cited: 2
Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms
Jutatip Panaampon, Prin Sungwan, Sawako Fujikawa, et al.
International Immunopharmacology (2024) Vol. 138, pp. 112612-112612
Closed Access | Times Cited: 2
Unraveling the complexities of colorectal cancer and its promising therapies – An updated review
Sayan Saha, Shreya Ghosh, Suman Ghosh, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113325-113325
Closed Access | Times Cited: 1
Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer
Ningning Zhang, Yuxin Huang, Guanwen Wang, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access
Construction of a CT Radiomics Model for Predicting Her2 Expression in Bladder Cancer Based on Random Forest Algorithm
Guoneng Zhang, Zeyu Chen, Wei Xia, et al.
Research Square (Research Square) (2024)
Closed Access
Molecular Aspects of BRAF and HER2 in prognosis of Periampullary Carcinoma
Apurva Apurva, Nimisha, Abhay Kumar Sharma, et al.
Pancreatology (2024) Vol. 24, Iss. 7, pp. 1084-1096
Closed Access
Advancements in Nuclear Imaging Using radiolabeled Nanobody tracers to support Cancer Immunotherapy
Katty Zeven, Yoline Lauwers, Lynn De Mey, et al.
Immunotherapy Advances (2024) Vol. 4, Iss. 1
Open Access
Insight into Binding and Interaction of Docking, Dynamics and Network Pharmacology to Explore the Target on Cancer Inhibitors
Ekambaram Gayathiri, Palanisamy Prakash, Thangaraj Pratheep, et al.
Journal of Pharmaceutical Innovation (2024) Vol. 19, Iss. 5
Closed Access
Monoclonal Antibody Therapies in Cancer Immunotherapy
Charuwan Thanawiroon, Bancha Yingngam
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 419-472
Closed Access
Protein Expression, Amplification, and Mutation of HER2 Gene in Canine Primary Pulmonary Adenocarcinomas: Preliminary Results
Barbara Brunetti, Dario de Biase, Francesca Millanta, et al.
Animals (2024) Vol. 14, Iss. 18, pp. 2625-2625
Open Access
The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
J. Haigh, Karan Patel, Samuel Rack, et al.
Current Oncology (2024) Vol. 31, Iss. 9, pp. 5652-5661
Open Access
Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery
Bengi Ruken Yavuz, Hyunbum Jang, Ruth Nussinov
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Allosteric antibodies: a novel paradigm in drug discovery
Léxane Fournier, Enrico Guarnera, Harald Kolmar, et al.
Trends in Pharmacological Sciences (2024)
Open Access
AKR1C mediates the acquired resistance to T-Dxd in a HER-2 positive gastric cancer line
Dong Wang, Qiu-Sha Huang, Peili Wang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1

Scroll to top